[HTML][HTML] Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
GI Smith, M Shankaran, M Yoshino… - The Journal of …, 2020 - Am Soc Clin Investig
The Journal of clinical investigation, 2020•Am Soc Clin Investig
BACKGROUND An increase in intrahepatic triglyceride (IHTG) is the hallmark feature of
nonalcoholic fatty liver disease (NAFLD) and is decreased by weight loss. Hepatic de novo
lipogenesis (DNL) contributes to steatosis in individuals with NAFLD. The physiological
factors that stimulate hepatic DNL and the effect of weight loss on hepatic DNL are not clear.
METHODS Hepatic DNL, 24-hour integrated plasma insulin and glucose concentrations,
and both liver and whole-body insulin sensitivity were determined in individuals who were …
nonalcoholic fatty liver disease (NAFLD) and is decreased by weight loss. Hepatic de novo
lipogenesis (DNL) contributes to steatosis in individuals with NAFLD. The physiological
factors that stimulate hepatic DNL and the effect of weight loss on hepatic DNL are not clear.
METHODS Hepatic DNL, 24-hour integrated plasma insulin and glucose concentrations,
and both liver and whole-body insulin sensitivity were determined in individuals who were …
BACKGROUND
An increase in intrahepatic triglyceride (IHTG) is the hallmark feature of nonalcoholic fatty liver disease (NAFLD) and is decreased by weight loss. Hepatic de novo lipogenesis (DNL) contributes to steatosis in individuals with NAFLD. The physiological factors that stimulate hepatic DNL and the effect of weight loss on hepatic DNL are not clear.
METHODS
Hepatic DNL, 24-hour integrated plasma insulin and glucose concentrations, and both liver and whole-body insulin sensitivity were determined in individuals who were lean (n = 14), obese with normal IHTG content (n = 26), or obese with NAFLD (n = 27). Hepatic DNL was assessed using the deuterated water method corrected for the potential confounding contribution of adipose tissue DNL. Liver and whole-body insulin sensitivity was assessed using the hyperinsulinemic-euglycemic clamp procedure in conjunction with glucose tracer infusion. Six subjects in the obese-NAFLD group were also evaluated before and after a diet-induced weight loss of 10%.
RESULTS
The contribution of hepatic DNL to IHTG-palmitate was 11%, 19%, and 38% in the lean, obese, and obese-NAFLD groups, respectively. Hepatic DNL was inversely correlated with hepatic and whole-body insulin sensitivity, but directly correlated with 24-hour plasma glucose and insulin concentrations. Weight loss decreased IHTG content, in conjunction with a decrease in hepatic DNL and 24-hour plasma glucose and insulin concentrations.
CONCLUSIONS
These data suggest hepatic DNL is an important regulator of IHTG content and that increases in circulating glucose and insulin stimulate hepatic DNL in individuals with NAFLD. Weight loss decreased IHTG content, at least in part, by decreasing hepatic DNL.
TRIAL REGISTRATION
ClinicalTrials.gov NCT02706262.
FUNDING
This study was supported by NIH grants DK56341 (Nutrition Obesity Research Center), DK20579 (Diabetes Research Center), DK52574 (Digestive Disease Research Center), and RR024992 (Clinical and Translational Science Award), and by grants from the Academy of Nutrition and Dietetics Foundation, the College of Natural Resources of UCB, and the Pershing Square Foundation.
The Journal of Clinical Investigation